Literature DB >> 25063689

Concurrent quantitative HPLC-mass spectrometry profiling of small selenium species in human serum and urine after ingestion of selenium supplements.

Sabine Kokarnig1, Alexandra Tsirigotaki2, Tanja Wiesenhofer1, Verena Lackner3, Kevin A Francesconi1, Spiros A Pergantis2, Doris Kuehnelt4.   

Abstract

Selenium metabolic patterns in the human body originating from five distinct selenium dietary sources, selenate, selenite, selenomethionine (SeMet), methylselenocysteine (MeSeCys) and selenized yeast, were investigated by performing concurrent HPLC-mass spectrometric analysis of human serum and urine. Total selenium and selenium species time profiles were generated by sampling and analyzing serum and urine from volunteers treated with selenium supplements, up to 5 and 24h following ingestion, respectively. We found that an increase in total serum selenium levels, accompanied by elevated selenium urinary excretion, was the common pattern for all treatments, except for that of selenite supplementation. Selenosugar 1 was a universal serum metabolite in all treatments, indicating that ingested selenium is favorably metabolized to the sugar. Except for selenite and selenized yeast ingestion, these patterns were reflected in the urine time series of the different treatments. Selenosugar 1 was the major selenium species present in urine in all treatments except for the selenate treatment, accounting for about 80% of the identified excreted species within 24h of ingestion. Furthermore, the urinary metabolite trimethylselenonium ion (TMSe) was detected for the first time in human background serum by using HPLC coupled to elemental and molecular mass spectrometry. The concurrent monitoring of non-protein selenium species in both body fluids provides the relation between bioavailability and excretion of the individual ingested species and of their metabolic products, while the combined use of elemental and molecular mass spectrometry enables the accurate quantitation of structurally confirmed species. This successfully applied approach is anticipated to be a useful tool for more extensive future studies into human selenium metabolism.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  HPLC-mass spectrometry; human serum; human urine; selenium metabolism; speciation

Mesh:

Substances:

Year:  2014        PMID: 25063689     DOI: 10.1016/j.jtemb.2014.06.012

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  6 in total

Review 1.  Selenium at the redox interface of the genome, metabolome and exposome.

Authors:  Jolyn Fernandes; Xin Hu; M Ryan Smith; Young-Mi Go; Dean P Jones
Journal:  Free Radic Biol Med       Date:  2018-06-05       Impact factor: 7.376

2.  Profiling of selenium absorption and accumulation in healthy subjects after prolonged L-selenomethionine supplementation.

Authors:  C Di Dato; D Gianfrilli; E Greco; M Astolfi; S Canepari; A Lenzi; A M Isidori; E Giannetta
Journal:  J Endocrinol Invest       Date:  2017-04-09       Impact factor: 4.256

3.  Effect of nonylphenol on the colonic mucosa in rats and intervention with zinc-selenium green tea (Camellia sinensis).

Authors:  Shixu Li; Mucong Zheng; Xuefeng Yang; Jianling Zhang; Jie Xu; Jie Yu
Journal:  Toxicol Res (Camb)       Date:  2021-12-29       Impact factor: 3.524

4.  Systematic study of the selenium fractionation in human plasma from a cancer prevention trial using HPLC hyphenated to ICP-MS and ESI-MS/MS.

Authors:  Christian L Ward-Deitrich; Emily Whyte; Christopher Hopley; Margaret P Rayman; Yasumitsu Ogra; Heidi Goenaga-Infante
Journal:  Anal Bioanal Chem       Date:  2020-11-02       Impact factor: 4.142

5.  The Association between the Urinary Excretion of Trimethylselenonium and Trimethylsulfonium in Humans.

Authors:  Bassam Lajin; Kevin A Francesconi
Journal:  PLoS One       Date:  2016-11-21       Impact factor: 3.240

6.  Selenium Kinetics in Humans Change Following 2 Years of Supplementation With Selenomethionine.

Authors:  Blossom H Patterson; Gerald F Combs; Philip R Taylor; Kristine Y Patterson; James E Moler; Meryl E Wastney
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.